Holen Sie sich die Stockscreener-App
25.77
0.39%
-0.10
Handel nachbörslich:
25.65
-0.12
-0.47%
Schlusskurs vom Vortag:
$25.87
Offen:
$26.01
24-Stunden-Volumen:
5.15M
Relative Volume:
1.61
Marktkapitalisierung:
$3.72B
Einnahmen:
$62.38M
Nettoeinkommen (Verlust:
$-101.59M
KGV:
-29.81
EPS:
-0.8644
Netto-Cashflow:
$-139.93M
1W Leistung:
-3.27%
1M Leistung:
+32.29%
6M Leistung:
+243.83%
1J Leistung:
+1,665%
1-Tages-Spanne:
$24.95
$26.05
1-Wochen-Bereich:
$24.95
$28.41
52-Wochen-Spanne:
$1.03
$28.41
Tango Therapeutics Inc Stock (TNGX) Company Profile
Firmenname
Tango Therapeutics Inc
Sektor
Branche
Telefon
(857) 320-4900
Adresse
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
25.77 | 3.72B | 62.38M | -101.59M | -139.93M | -0.8644 |
VRTX
Vertex Pharmaceuticals Inc
|
430.29 | 109.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.57 | 79.46B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
780.25 | 48.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.54 | 40.77B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
300.80 | 33.39B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-02-23 | Eingeleitet | Mizuho | Outperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-08 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten
Does Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect? - MSN
Tango Therapeutics is the best performing healthcare stock in March - MSN
Tango Therapeutics (TNGX) price target increased by 32.09% to 20.06 - MSN
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
[Form 3] Tango Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
CFO Matthew Gall (TNGX) files Form 3 with no reported trades - Stock Titan
Tango Therapeutics stock hits all-time high at 27.16 USD By Investing.com - Investing.com India
Tango Therapeutics stock hits all-time high at 27.16 USD - Investing.com
354,192 Shares in Tango Therapeutics, Inc. $TNGX Bought by Mass General Brigham Inc - MarketBeat
Stifel reiterates Tango Therapeutics stock rating on combo potential By Investing.com - Investing.com South Africa
Stifel reiterates Tango Therapeutics stock rating on combo potential - Investing.com
HBS1L degradation inducers named in Tango Therapeutics patent - BioWorld News
Tango Therapeutics (TNGX) Stock Stop Loss (Eye on Rally) 2026-04-18Stock Ideas - UBND thành phố Hải Phòng
Is Tango Therapeutics’ New Leadership Bench Reframing Its R&D Ambitions or Its Risk Profile (TNGX)? - simplywall.st
Is Tango Therapeutics (TNGX) Building the Right Leadership Mix to Navigate Complex Oncology Pipelines? - Yahoo Finance
Tango Therapeutics (NASDAQ: TNGX) details 2026 virtual meeting, director elections and pay vote - Stock Titan
Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells 38,460 Shares of Stock - MarketBeat
Tango Therapeutics president sells $961k in stock By Investing.com - Investing.com Canada
Tango Therapeutics president sells $961k in stock - Investing.com
Tango Therapeutics (TNGX) R&D president exercises options and sells stock - Stock Titan
Tudor Investment Corp ET AL Acquires New Holdings in Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat - Sahm
Tango Therapeutics Overhauls Finance Leadership Amid Clinical Push - TipRanks
Tango Therapeutics names Matthew Gall as chief financial officer By Investing.com - Investing.com South Africa
New CFO and senior leaders join Tango Therapeutics (NASDAQ: TNGX) - Stock Titan
Tango Therapeutics names Matthew Gall as chief financial officer - Investing.com
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of ... - Bluefield Daily Telegraph
Tango Therapeutics Inc stock hits all-time high of 22.21 USD - Investing.com Australia
Tango Therapeutics (NASDAQ:TNGX) Reaches New 52-Week HighHere's What Happened - MarketBeat
Tango Therapeutics Inc stock hits all-time high of 22.21 USD By Investing.com - Investing.com South Africa
Leerink raises Tango Therapeutics stock price target on PDAC data By Investing.com - Investing.com South Africa
Update Report: Is Tango Therapeutics Inc in a long term uptrendCEO Change & Smart Money Movement Tracker - baoquankhu1.vn
Leerink raises Tango Therapeutics stock price target on PDAC data - Investing.com
Performance Recap: Will Tango Therapeutics Inc benefit from rising consumer demand2026 Macro Moves & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Tango Therapeutics (NASDAQ:TNGX) Shares Gap UpTime to Buy? - MarketBeat
Momentum Shift: Will Tango Therapeutics Inc stock go up in YEARWeekly Profit Recap & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Moving Averages: Will Tango Therapeutics Inc benefit from rising consumer demandM&A Rumor & Weekly High Momentum Picks - baoquankhu1.vn
TNGX Should I Buy - Intellectia AI
Stifel and Jefferies raise targets on Tango Therapeutics (TNGX) - MSN
Can Tango Therapeutics (TNGX) Stock Recover Now | Price at $20.82, Up 3.79%Crowd Signals - Cổng thông tin điện tử tỉnh Lào Cai
Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets - The Globe and Mail
Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.01%
0.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):